Table 2.
Changes from baseline to follow-up in laboratory parameters and noninvasive fibrosis markers (n=172).
| Variable | Baseline | Follow-up | Change from baseline (%) | P value |
|---|---|---|---|---|
| Laboratory parameters | ||||
| Platelets (×109/L) | 208.55 (76.9) | 224.57 (82.4) | 7.7 | .003 |
| Hemoglobin (g/L) | 137.39 (20.3) | 135.51 (22.0) | −1.4 | .415 |
| ALT (IU/L) | 71.25 (60.6) | 26.02 (14.5) | −63.5 | <.001 |
| AST (IU/L) | 55.77 (41.7) | 22.43 (11.0) | −59.8 | <.001 |
| ALP (IU/L) | 109.73 (48.5) | 92.39 (38.7) | −15.8 | <.001 |
| Albumin (g/L) | 37.05 (9.1) | 38.88 (4.7) | 4.9 | .010 |
| Bilirubin (μmol/L) | 11.29 (5.6) | 10.66 (7.6) | −5.6 | .393 |
| Noninvasive fibrosis markers | ||||
| LSM (kPa) | 15.09 (11.4) | 10.19 (7.4) | −32.5 | <.001 |
| CAP (dB/m) | 234.11 (59.6) | 241.70 (64.7) | 3.2 | .274 |
| AST/ALT | 0.86 (0.32) | 0.95 (0.41) | 10.5 | .015 |
| FIB-4 | 1.99 (1.4) | 1.35 (0.9) | −32.2 | <.001 |
| APRI | 0.81 (0.7) | 0.34 (0.2) | −58.0 | <.001 |
Data are mean and standard deviation. ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; LSM: liver stiffness measurement; CAP: controlled attenuation parameter; FIB-4: fibrosis-4; APRI: AST to platelet ratio index.